The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|April 2, 2011
- Pharmaceutical Technology-04-02-2011
- Volume 35
- Issue 4
Pharmaceutical Technology North America, April 2011
Solid Dosage and Excipients
Advertisement
Articles in this issue
over 15 years ago
In the Spotlight April 2011over 15 years ago
Health-Reform Controversiesover 15 years ago
Biotechnology Loses Lead in Fundingover 15 years ago
Celebrity Couples to Disuniteover 15 years ago
Report From Chinaover 15 years ago
Scrutinizing the Subvisibleover 15 years ago
When Patience Pays Offover 15 years ago
Advancing Small-Molecule SynthesisAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
2
AI Formulation: Regulators Want Data
3
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5